Opendata, web and dolomites


Imaging NM: A Nanoparticulate Precision Medicine Approach to Target Cancer

Total Cost €


EC-Contrib. €






 INTACT project word cloud

Explore the words cloud of the INTACT project. It provides you a very rough idea of what is the project "INTACT" about.

treat    platform    trials    assures    time    develops    neutropenia    2024    superior    reg    therapeutic    options    market    patient    maximum    10fte    selectively    gt    therapeutics    projected    close    nanomedicines    significantly    nanoparticles    validate    generation    finalizing    biodistribution    truly    100m    nanomedicine    personalized    limited    cripec    perform    clinical    receive    launch    preclinically    alopecia    treatment    site    deals    licensing    oncologists    deal    tracer    pet    efficacy    enhanced    drug    boost    inappropriate    docetaxel    intact    adverse    medicine    profile    pharmacokinetic    cancer    ovarian    business    heterogeneity    gap    worldwide    2022    whereby    exposing    cristal    diseases    personalisation    appropriate    bladder    safety    revenues    drugs    ct    insufficient    performance    correlated    exhibit    89zr    trial    death    decorated    patients    generate    visualize    avoids    lab    turns    causes    tumour    demonstrated    exceeding   

Project "INTACT" data sheet

The following table provides information about the project.


Organization address
address: OXFORDLAAN 55
postcode: 6229 EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 8˙996˙610 €
 EC max contribution 2˙499˙999 € (28%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CRISTAL DELIVERY BV NL (MAASTRICHT) coordinator 2˙499˙999.00


 Project objective

Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer. Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s). The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product CriPec® docetaxel and a promising clinical phase I trial is finalizing, providing a significantly increased pharmacokinetic and safety profile. CT already observed activity in patients and much reduced neutropenia and alopecia. In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection. This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment. CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More